Shilpa Medicare Limited at the Board of Directors meeting held on 11 August 2022, approved reconstituted the Committees of Board by inducting Mr. Arvind Vasudeva, Independent Director
in the Audit Committee, Dr. Anita Bandyopadhyay, Additional Independent Director in the CSR Committee as Chairperson & as a member in Nomination & Remuneration Committee and Dr. Kamal K Sharma as a member in Stakeholders Relationship Committee & Risk Management Committee. Appointment of Dr. Anita Bandyopadhyay, as an Additional Women Independent Director of the Company to hold office upto the date of upcoming Annual General Meeting. Effective date of appointment is 11 August 2022. Anita Bandyopadhyay holds Doctorate degree in Applied Psychology from Kolkata University and Executive MBA from SP Jain Institute of Management & Research, Mumbai. She is an acclaimed HR consultant with extensive expertise in Leadership Development, Talent Management, Performance Management, HR Processes and corporate succession planning. She has an amalgamation of strong conceptual knowledge with result-oriented application practice. She has serviced Pharmaceuticals, Glass Packaging, Education, Adhesives, Textile & Apparels Industries and has exposure to Manufacturing, Education, FMCG, Retail and B2B business sectors. Directorship in listed Companies: Ami Organics Limited; Speciality Restaurants Limited. Chairperson of Stakeholders Relationship Committee in Speciality Restaurants Limited and a Member of Nomination and Remuneration Committee in the aforesaid listed entities.
Shilpa Medicare Limited is an India-based pharmaceutical company. The Company is engaged in the manufacturing of active pharmaceutical ingredients (APIs), formulation and development service. It is engaged in APIs, intermediates, formulations, new drug delivery systems, peptides / biotech products and specialty chemicals, and others. The Company supplies more than 30 oncology APIs including key products such as Capecitabine, Gemcitabine Hydrochloride, Pemetrexed, Axitinib, Erlotinib Hydrochloride and Irinotecan Hydrochloride for various international markets including United States of America, Europe, Japan, South Korea, Russia, Mexico, Brazil, and other emerging markets. Its non-Oncology API products include Ambroxol (Mucolytic agent), Tranexmic Acid and Ursodeoxycholic Acid. Its Injectable Dosage Forms include Myelodysplastic Syndrome, Breast Cancer, Multiple Myeloma, and more. Its Oral Solid Dosage Forms include Psoriasis, Prostate Cancer, Multiple Sclerosis, and others.
SHILPA MEDICARE LIMITED 
